SPOTLIGHT: BMS selling off ConvaTec unit for $4.1B


Bristol-Myers Squibb continues to off-load parts of its business that aren't directly related to its beef-up-biopharma strategy: the company has agreed to sell its wound and ostomy care division ConvaTec to a private equity partnership for $4.1 billion. Release | Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.